Expanded partnership to help increase patient access to critical genetic screening services including genetic counseling and test result turnaround time 

HOUSTON, March 29, 2024 /PRNewswire/ -- The Prelude Network® (Prelude), the largest network of fertility clinics in North America, announced today an expansion of its partnership with Labcorp (NYSE: LH), a global leader of innovative diagnostic and biopharma laboratory services, to serve as its Preferred Genetic Carrier Screening Lab.

Transaction to enhance Labcorp's laboratory services network and expand access to the company's high-quality clinical laboratory services

BURLINGTON, N.C. and MIAMI, March 28, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health, Inc. (Nasdaq: OPK), a multinational biopharmaceutical and diagnostics company, announced today that they have entered into an agreement for Labcorp to acquire select assets of BioReference Health, a wholly owned subsidiary of OPKO Health.

BURLINGTON, N.C., March 27, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the first quarter of 2024 before the market opens on Thursday, April 25, 2024. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website.

Addition of pTau217 test further expands the company's leadership in testing options for Alzheimer's disease to improve patient care 

BURLINGTON, N.C., March 20, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch and immediate availability of its test to identify the presence or absence of phosphorylated tau 217 (pTau217), a pivotal blood biomarker designed to aid in the diagnosis of Alzheimer's disease and the subsequent monitoring of patients undergoing treatment with new Alzheimer's disease therapies. Labcorp's pTau217 test can be ordered by physicians and used in clinical trials and research by global biopharmaceutical partners.

Outcomes point to value of biomarker testing in addressing testing gaps in clinical practice

BURLINGTON, N.C., March 16, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today presented the results from two studies at the 2024 SGO Annual Meeting on Women's Cancer. The studies demonstrate the value of biomarker testing in closing testing gaps and guiding targeted therapies for patients with epithelial ovarian cancer (EOC).

New offering to support individuals and physicians with accessible and convenient testing options to guide weight loss management decisions and treatments

BURLINGTON, N.C., March 7, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the introduction of its Weight Loss Management portfolio. The new offering features educational resources and convenient testing solutions, equipping individuals and their physicians with baseline and ongoing health indicators to inform treatment options, including lifestyle modifications, Glucagon-like peptide-1 (GLP-1) medications or bariatric surgery.

Company Provides 2024 Guidance

BURLINGTON, N.C., Feb. 1, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, has once again been named to FORTUNE® magazine's list of the World's Most Admired Companies™, a recognition of the most respected and reputable companies globally.

"Labcorp is honored to be included on this year's FORTUNE World's Most Admired Companies list," said Adam Schechter, chairman and CEO of Labcorp. "This recognition is a testament to the hard work and dedication of Labcorp employees who work tirelessly to help address some of the world's most important health challenges and support our mission to improve health and improve lives."

B•R•A•H•M•S™ sFlt-1/PlGF KRYPTOR™ Test System is available through physicians and is the first FDA-cleared biomarker test to aid in the risk assessment of progression to preeclampsia with severe features, a leading cause of maternal and fetal mortality in the U.S.1

BURLINGTON, N.C., Jan. 31, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the launch and availability of a new, FDA-cleared blood test for risk assessment and clinical management of severe preeclampsia, a life-threatening blood pressure disorder that occurs during pregnancy and the postpartum period.

BURLINGTON, N.C., Jan. 16, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the fourth quarter and full year 2023 before the market opens on Thursday, February 15, 2024. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website.

BURLINGTON, N.C., Jan. 12, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on March 13, 2024, to stockholders of record as of the close of business on February 27, 2024.

About LabcorpLabcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's more than 60,000 employees serve clients in over 100 countries, worked on over 80% of the new drugs approved by the FDA in 2022 and performed more than 600 million tests for patients around the world. Learn more about us at www.Labcorp.com

Collaboration Aims to Improve Patient Experience, Accessibility and Efficiency in Decentralized Clinical Trials

BURLINGTON, N.C. and LAFAYETTE, Calif., Jan. 10, 2024 /PRNewswire/ -- Labcorp, a global leader of innovative and comprehensive laboratory services, and Hawthorne Effect, Inc., a complete clinical trials solution integrating technology, are pleased to announce a strategic collaboration to advance decentralized clinical trial capabilities for pharma, biotech and medical device sponsors seeking to increase patient diversity and inclusion, decrease site burden, and accelerate enrollment and clinical study timelines.

BURLINGTON, N.C., Jan. 2, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that members of the executive management team will participate in a fireside chat at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 9 at 4:30 p.m. (PT).

A live audio webcast of the fireside chat will be available via the Company Investor Relations website at ir.Labcorp.com and archived for replay. 

Agreement Expands Access to Labcorp's Diagnostics Capabilities and Services

BURLINGTON, N.C., Nov. 20, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the completion of the previously announced transaction with Legacy Health to acquire select assets of Legacy's outreach laboratory business. Labcorp also now manages Legacy's inpatient hospital laboratories through a long-term agreement to provide staffing, leadership, scientific knowledge, analytics, supply chain services and laboratory support. 

BURLINGTON, N.C. and WASHINGTON, Nov. 16, 2023 /PRNewswire/ -- Today, the Tigerlily Foundation  (Tigerlily), a leading breast cancer patient advocacy organization, and Labcorp, a global leader of innovative and comprehensive laboratory services, announced the launch of I AM INCLUDED, a co-developed, modernized, multi-stakeholder framework for sharing best practices of U.S. diverse clinical trial site leaders for inclusive cancer clinical trials. 

Expanded offering adds inclusive end-to end support for pre-conception, adoption and surrogacy while removing barriers to equitable care access

BOSTON, Nov. 8, 2023 /PRNewswire/ -- Ovia Health by Labcorp (Ovia) today announced it will offer a first-of-its-kind Fertility and Family Building Benefit, providing companies and health plans a comprehensive and customizable solution to support the diverse family-building journeys of their employees and health plan members.

Company Updates Full-Year Guidance

BURLINGTON, N.C., Oct. 12, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on December 12, 2023, to stockholders of record as of the close of business on November 8, 2023.

About LabcorpLabcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's more than 60,000 employees serve clients in over 100 countries, worked on over 80% of the new drugs approved by the FDA in 2022 and performed more than 600 million tests for patients around the world. Learn more about us at www.labcorp.com.

Test is available through physicians for use with patients being evaluated for possible Alzheimer's disease or other causes of cognitive impairment

Labcorp is the first company to deliver a blood-based Amyloid-Tau-Neurodegeneration (ATN) Profile, which uses a trio of blood biomarkers to detect the hallmarks of Alzheimer's disease

BURLINGTON, N.C., Oct. 11, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch and national availability of its ATN Profile, a blood-based test that combines three, well-researched blood biomarkers to identify and assess biological changes associated with Alzheimer's disease – amyloid plaques, tau tangles and neurodegeneration (ATN) – which can help accelerate the path to diagnosis and intervention.i The test is available through physicians for use with patients who are being evaluated for possible Alzheimer's disease or other causes of cognitive impairment based on clinical observation and cognitive screenings. 

Labcorp to acquire Baystate Health's outreach laboratory business and select operating assets

Collaboration to improve access and enhance affordable, high-quality healthcare services for underserved communities across Massachusetts

BURLINGTON, N.C., Oct. 4, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today it will acquire Baystate Health, Inc.'s (Baystate Health) outreach laboratory business and select operating assets, including laboratory service centers operated by Baystate Health throughout Massachusetts. This strategic relationship will build upon Labcorp's and Baystate Health's existing reference laboratory relationship to improve the efficiency of routine and specialty lab testing.